MedTrace Logo

Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

NCT00006232 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-05-15

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for multiple myeloma.

PURPOSE: This randomized phase III trial is comparing two combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III multiple myeloma.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

dexamethasone

DRUG

doxorubicin hydrochloride

DRUG

idarubicin

DRUG

vincristine sulfate

Sponsors & Collaborators

  • West of Scotland Lymphoma Group

    lead OTHER

Principal Investigators

  • Gordon Cook, MD, PhD · Leeds Cancer Centre at St. James's University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-10-31
Completion
2007-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006232 on ClinicalTrials.gov